Up­dat­ed: Zymeworks want­ed a Big Phar­ma part­ner for its bis­pe­cif­ic. Jazz Phar­ma­ceu­ti­cals said OK

Speak­ing in a Star­bucks booth on the side­lines of AS­CO in June, Ken­neth Gal­braith em­pha­sized he want­ed what Dai­ichi Sankyo got for its HER2 break­out drug: a Big Phar­ma part­ner that could turn its bis­pe­cif­ic in­to a world­wide med.

While not quite the size of an As­traZeneca, Gal­braith’s Zymeworks has lined up a sec­ond part­ner for its HER2 bis­pe­cif­ic an­ti­body, known as zanidatam­ab. In comes neu­ro­science and on­col­o­gy drug­mak­er Jazz Phar­ma­ceu­ti­cals, it­self eye­ing up to $3.7 bil­lion in rev­enue this year, who will be dol­ing out an ini­tial $50 mil­lion to nab the de­vel­op­ment and com­mer­cial­iza­tion rights for all in­di­ca­tions of the late-stage as­set in most mar­kets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER